(Q43521752)
Statements
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis (English)
M Montemurro
H Gelderblom
U Bitz
J Schütte
J Trent
F Duffaud
6 November 2012